Al pathology in #immunooncology research Watch the video or download the poster below to learn about how to train models which predict #cellstatus in #hematoxylin and eosin stains. ow.ly/Yy9C50OQfgT

Broadening I–O clinical trial participation to improve #healthequity & diversity: current perspectives & future plans #immunooncology Read the article here: ow.ly/TRcX50OVtIm

Better together: assessing the evolving #combinationtherapy picture in I–O #immunooncology Read this interview below: ow.ly/nI2E50OVvSZ

Achieving more patient-centered trials in #cancerimmunotherapy: a #patientadvocate perspective Read the article below: ow.ly/wh3J50P5gzp

Targeting EGFR to enhance NKT cell-mediated killing of #lungcancercells Register for this webinar to learn about improvements to the treatment of #lungcancer: ow.ly/NXKi50P5hfe

FastFacts now available! Using a data-driven approach to deliver complex studies in #advancedtherapeutics #celltherapy #studytimelines Watch the video or view the poster below: ow.ly/WxZn50P6s3u

ASGCT turns the spotlight on immuno-oncology: where have we been & where are we going? Read this interview with Hans-Peter Kiem: ow.ly/uF9v50PhlvT

Mapping #immunotherapy sensitivity with multi-omic approaches In this interview, Arutha K (Group Leader, Frazer Institute, The University of Queensland) gives insight on applying multi-omic approaches to understand the #tumor microenvironment. ow.ly/QbCm50PnwCS

#Podcast now available! Experts recently took part in a Podcast to discuss application of multiomics to novel target discovery in immuno-oncology Listen to the podcast or read the transcript at your convenience: ow.ly/5qWh50Pw41C

#CAR-T: Why not me? In this #webinar, an expert panel will discuss how feasible it is to predict the potential of therapies based on patients’ #immunological states Register below: buff.ly/46LKHAR

2024 and beyond: addressing ongoing safety and toxicity challenges for the future of the I-O field Read this #article on addressing the safety and toxicity hurdles in the #Immuno-#oncology field today. buff.ly/46zeo7E

#Multiomics integration: advancing pediatric cancer #immunotherapy Read this #interview where the role of multiomics in the I-O setting and how these tools can be leveraged to improve pediatric cancer care are discussed buff.ly/47KjTRY

Don’t miss out on the June #Immuno-oncology Insights issue! Featuring spotlight content on: Overcoming mechanisms of #tumorresistance Read below: buff.ly/4ajzMRt #immunotherapy #celltherapy

Don’t miss out on the November #Immuno-oncology Insights issue! Featuring spotlight content on: Safety: #preclinical and clinical Read below: buff.ly/3RLdLTa #immunotherapy #celltherapy

#Interview now available! Advancing #immunotherapy and data-driven research Read this interview where the latest developments in data-driven technology for the I-O space is discussed buff.ly/4bdSXMT

#Myeloidcells: unveiling their secrets as #biomarkers through next-generation sample preparation View this #FastFacts on federico forconi Laminar Wash™ technology as it provides improvements in #myeloidcellcharacterization buff.ly/4alOhnf

#Myeloidcells: unveiling their secrets as #biomarkers through next-generation sample preparation The @Curiox Laminar Wash™ technology provides improvements in #myeloidcellcharacterization View this #FastFacts below: buff.ly/4alOhnf

Same-section spatial #multiomics: a platform for detailed analysis of the #solidtumorTME In this #webinar, technologies that allow for same-section #spatialmultiomics and simultaneous protein and #RNAdetection are explored. Register below: buff.ly/3Kf5yDp

The preclinical journey: transitioning a novel #celltherapy into early phase #clinicaltrials This #interview covers pioneering a chimeric auto-#antibodyreceptor to target B-cell-mediated diseases. Read below: buff.ly/3YDO9MS

Emerging trends in #celltherapies for cancer This #webinar will review the current trends in the development of cell therapies for cancer Register below: buff.ly/4eSf6lu #immunooncologytherapies #autologouscelltherapies